Medicine, Human Health Technology Offers

Núria Brunet i Garcia posted this:
Licensing Manager at Universitat de Lleida

New therapeutic candidate for Spinal Muscular Atrophy We are looking for a licensing agreement with a company with expertise in the field of neurosciences. More particularly, we are willing to find a company involved in the development of therapeutic solutions for the rare disease Spinal Muscular Atrophy (SMA).

Maria João Cardoso posted this:
Science and Technology Manager at UATEC - Unidade de Transferência de Tecnologia

Innovative methodology for nanoencapsulation of montelukast in cyclodextrin Cyclodextrin is a nano-sized capsule that allows increasing the stability and aqueous solubility of active pharmaceutical ingredients such as montelukast. This technology comprehends an alternative method to obtain an amorphous solid composed by montelukast and cyclodextrin. In alternative to conventional methodologies, this method allows the encapsulation to occur without requiring the use of solvents and the formation of degradation products.

Maria João Cardoso posted this:
Science and Technology Manager at UATEC - Unidade de Transferência de Tecnologia

Separation of nucleic acids using chromatographic matrices functionalized with ionic liquids Novel multimodal chromatographic supports prepared by functionalizing matrices with ionic liquids, allowing the separation of RNA and DNA in a single chromatographic step with high selectivity, robustness and reproducibility. In comparison to other commercially available supports, a higher dynamic binding capacity for RNA was obtained.

UNIVERSIDAD DE BURGOS posted this:

Method of preparation and use of derivatives of perylene-diimide (PDI) in different applications such as bioimaging or biomarkers.The present invention provides a methodology for the synthesis of derivatives of perylene-diimide (PDI, for which there was no obtention process, and its use in different applications such as bioimaging or biomarkers.

Yissum - Research Development Company of the Hebrew University posted this:

A novel target for the treatment of genetic diseases caused by nonsense mutations A novel target for the treatment of genetic diseases caused by nonsense mutations Project ID : 6-2018-4579

Lucas Montes posted this:
Technology Transfer Advisor at University of Granada (OTRI)

Biomimetic magnetic nanoparticles for its use in biotechnological applications The present invention provides a composition which contains nanoparticles of magnetite made in presence of magnetosome proteins expressed as recombinant. These nanoparticles are biocompatibles, have a negative charge at physiological pH and a size higher tan 30nm, considered in the range of the singular magnetic domain, for different uses in the field of biotechnology, as well as for its use for for drug administration for the treatment of cancer.

Universidad de Granada posted this:

Method for isolating circulating epithelial pulmonary cells and their use as markers for diagnosing Chronic Obstructive Pulmonary Disease (COPD)A procedure is described based on Liquid Biopsy techniques that allows both the diagnosis of COPD, as well as its evolution in patients. In order to do that, circulating pulmonary cells (CPCs) that could be present in blood of patients diagnosed with COPD are detected and characterized by combining two different techniques: - Immunogenetic positive selection for their isolation in peripheral blood. - Immunocytochemistry for detecting CPCs by using specific markers for pulmonary epithelial cells.

Russell Nicholls posted this:
Licensing Manager at Curtin University

Rhenium compounds as anticancer agents Metal-based anticancer agents, such as cisplatin, are used as gold standard cancer therapies. While these drugs are effective in eradicating malignant cells, their selectivity is poor, meaning that significant adverse effects are experienced during treatment through damage inflicted on healthy cells. Improved selectivity and targeted cancer therapies with minimal side effects are being sought. Many drugs have been developed which contain platinum, and other metals are now being developed as anticancer agents. Researchers at Curtin University developed a series of rhenium containing compounds that target cancerous cells and block their growth. These compounds are promising candidates for treatment of tumours with aggressive potential for metastasis (for example, pancreatic cancer). A library of molecular candidates have been synthesized, and structure-activity relationship to modulate selectivity and therapeutic potential has been explored.

Yissum - Research Development Company of the Hebrew University posted this:

Novel Indoline Derivatives as Anti-Inflammatory Agents for the Treatment of Diabetes Novel Indoline Derivatives as Anti-Inflammatory Agents for the Treatment of Diabetes Project ID : 7-2015-3171

Yissum - Research Development Company of the Hebrew University posted this:

SpliSense Modulation of the CFTR gene splicing for treatment of CF Project ID : 26-2016-4370

Yissum - Research Development Company of the Hebrew University posted this:

Tissue Dynamics A company that provides services for toxicity level in molecules- for Pharma companies, maybe will produce a kit Project ID : 6-2017-4402

Yissum - Research Development Company of the Hebrew University posted this:

OnTimeBio LTD OnTimeBio is developing a highly sensitive blood test to enable timely detection and monitoring of diseases. OnTimeBio's product utilizes advanced computational approaches with genomic and epigenomic approaches in order to enable a quantitative and exact readout of tissue dynamics across the organs of the human body. Applying the technology across multiple diseases, including cancer, metabolic, autoimmune, and neurodegenerative diseases, can reduce patient suffering and enable better treatment outcomes while lowering healthcare costs. For developers of novel therapeutics, the technology provides a lens to the body's response across all targeted tissues. This allows better patient stratification and precise and swift monitoring of patients' responses to new therapies. Project ID : 26-2017-4403

Yissum - Research Development Company of the Hebrew University posted this:

Novel Transdermal Delivery System of Cannabinoids Cluster9 Cannabinoids Transdermal, enhanced and modulated administration due to an innovative biphasic composition Project ID : 6-2016-4334

Universidad de Alcalá-OTRI posted this:

Derivatives of Indolin-2-one and its therapeutic use in inflammatory, autoimmune, metabolic, cardiovascular, neurological and cancer diseases.The research group of “Neuroendocrinology of the cannabinoid / vanilloid system” of the University of Alcalá, in collaboration with researchers from the Institute of Medical Chemistry of CSIC, have developed a series of compounds derived from indolin-2-one, emphasizing the pharmaceutical compositions containing in the compounds and their use for the treatment of diseases mediated by AMPK (AMP-activated kinase), particularly inflammatory, autoimmune, metabolic, cardiovascular, neurological and cancer. The group is looking for companies in the pharmaceutical and health sector with the objective of reaching technical cooperation agreements, commercial agreements with technical assistance or patent licensing.

Mª Eugenia Garcés Castellote posted this:
Commercialization Specialist at Universidad de Alcalá-OTRI

New inhibitor compounds of the tyrosine phosphatase 1B protein The research group in "Biological Chemistry" of the University of Alcalá has developed new compounds inhibitors of the Tyrosine Phosphatase 1B Protein, which are related to new Formulas I, II and III, with methods to prepare them, with the use of them as inhibitors of protein tyrosine phosphatase 1B (PTP1B) and with the use of the intermediates that lead to that compounds to prepare an inhibitor of PTP1B comprised by that formulas. These compounds have application in the treatment or prevention of diseases in which it is known that PTP1B is involved in the pathogenesis, so they can be used for the treatment of insulin resistance, glucose intolerance, obesity, diabetes mellitus, hypertension and ischemic diseases of large and small blood vessels, conditions that accompany type 2 diabetes and other disorders where insulin resistance is indicated. The group looks for companies in the health and pharmaceutical sector with the aim of reaching technical collaboration agreements, commercial agreements or patent licenses agreements.

Medicine, Human Health Technology Offers

Innovation Resources

Sitemaps

Support

Company

Top Posts Categories

Recognitions

Log in to find novel technologies and contact researchers

Medicine, Human Health Technology Offers

Recognitions

Follow us

Log in to find novel technologies and contact researchers